lopinavir has been researched along with Clerambault Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Achan, J; Bangirana, P; Banik, A; Boivin, MJ; Giron, LB; Pillai, SK; Ruel, TD; Sikorskii, A | 1 |
| Abach, J; Arenas-Pinto, A; Hakim, J; Hoppe, A; Kambugu, A; Kwobah, C; Mwebaze, R; Paton, NI; Thompson, J; Tumukunde, D; van Oosterhout, JJ; Walker, SA | 1 |
2 trial(s) available for lopinavir and Clerambault Syndrome
| Article | Year |
|---|---|
Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Lopinavir; Male; Neurocognitive Disorders; Reverse Transcriptase Inhibitors; Uganda | 2017 |
Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; CD4 Lymphocyte Count; Cognition; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Neurocognitive Disorders; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2016 |